7月16日，Erasca盘中下跌5.27%，报20.14美元/股，成交额3885.03万美元。
消息面上，公司于同日宣布已完成此前公布的扩大规模普通股公开发行，以每股17.50美元的价格发行超过3610万股普通股，募集总额约6.325亿美元，其中包括承销商全额行使超额配售权所售出的逾470万股。该发行规模较最初计划的5亿美元显著扩大，且发行价格低于当前交易价，市场对大额股权稀释的担忧成为股价承压的主要因素。
公司表示，净募集资金将连同现有现金及投资，用于资助产品候选药物的研发及其他开发项目。Erasca是一家临床阶段精准肿瘤学公司，专注于为RAS/MAPK通路驱动的癌症患者发现、开发和商业化疗法。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.